#4-16E. Navigating RA-ILD Therapies: Target Trial Emulation (SeminArthritisRheum, 2026)

Are you struggling to choose the optimal immunosuppressive therapy for patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)? This episode explores a recent target trial emulation utilizing United States Medicare data to compare the effectiveness of various biologic and targeted synthetic DMARDs, including abatacept, JAK inhibitors, IL-6 inhibitors, and TNF inhibitors, against rituximab. The study found no statistically significant differences in the primary composite outcome of respiratory hospitalization, lung transplant, or death across the treatment groups in the primary intention-to-treat analyses. However, the crucial clinical takeaway stems from secondary analyses revealing that both abatacept and JAK inhibitors were associated with a significantly reduced risk of all-cause mortality compared to rituximab. While these findings offer valuable guidance for clinical decision-making in an area lacking robust randomized controlled trials, it is essential to critically appraise the observational study design. Specifically, despite rigorous propensity score matching, residual confounding by indication remains a key limitation, as rituximab might have been preferentially prescribed to patients with more severe lung disease. Ultimately, this evidence supports considering abatacept and JAK inhibitors as viable alternatives in RA-ILD management while awaiting definitive clinical trials.

Citation: Gregory C McDermott, Daniel H Solomon, Jeffrey A Sparks, Rishi J Desai. Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. Seminars in Arthritis & Rheumatism. 2026. DOI: https://doi.org/10.1016/j.semarthrit.2026.152973

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.